Telmisartan as metabolic modulator: a new perspective in sports doping?

J Strength Cond Res. 2012 Mar;26(3):608-10. doi: 10.1519/JSC.0b013e31824301b6.

Abstract

The World Antidoping Agency (WADA) has introduced some changes in the 2012 prohibited list. Among the leading innovations to the rules are that both 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (peroxisome proliferator-activated receptor-δ [PPAR-δ]-5' adenosine monophosphate-activated protein kinase [AMPK] agonist) and GW1516 (PPAR-δ-agonist) are no longer categorized as gene doping substances in the new 2012 prohibited list but as metabolic modulators in the class "Hormone and metabolic modulators." This may also be valid for the angotensin II receptor blocker telmisartan. It has recently been shown that telmisartan might induce similar biochemical, biological, and metabolic changes (e.g., mitochondrial biogenesis and changes in skeletal muscle fiber type) as those reported for the former call of substances. We suspect that metabolic modulators abuse such as telmisartan might become a tangible threat in sports and should be thereby targeted as an important antidoping issue. The 2012 WADA prohibited list does not provide telmisartan for a potential doping drug, but arguments supporting the consideration to include them among "metabolic modulators" are at hand.

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers* / pharmacology
  • Animals
  • Benzimidazoles* / pharmacology
  • Benzoates* / pharmacology
  • Doping in Sports*
  • Humans
  • Mice
  • Muscle, Skeletal / drug effects
  • Rats
  • Telmisartan

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Benzimidazoles
  • Benzoates
  • Telmisartan